What the clinical trials tell us about injection sites The landmark phase 2 trial for retatrutide, published in the New England Journal of Medicine (Jastreboff et al., 2023), enrolled 338 adults with obesity
This dual action reduces the risk of hyperglycemia and other complications associated with diabetes
While MYC is a well-characterized human oncogene, systemic suppression of MYC as a targeted human longevity intervention is currently unproven and remains confined to transgenic mouse models and in vitro assays
Large population studies have shown that unexplained B12 levels above 813 pg/mL are associated with an increased risk of cancer diagnosis within one year, though the absolute risk for any individual is still relatively low
This makes the targets genuinely hard for our binder design: the model has not seen a closely related protein in a bound context during training
Research-grade BPC-157 powders sold online are not regulated for human use, sterility, or identity verification